UCB SA (UCB) posted higher full-year 2011 net profit of 235 million euros compared with 103 million euros in 2010, while adjusted net profit decreased to 225 million euros from last year's 239 million euros. Core net profit amounted to 337 million euros, down 6%, at actual rates, from 359 million euros in the comparable period.
On a per share basis, basic earnings for the recent year were 1.32 euros, higher than 0.57 euros reported a year ago, with core earnings per share falling to 1.89 euros from 1.99 euros in the earlier year period, reflecting the impact from accelerated research and development expenses.
Revenue increased 1% to 3.25 billion euros in 2011, from 3.22 billion euros in the prior year. Full-year net sales amounted to 2.88 billion euros or 3% higher than 2010's 2.79 billion euros, because of the solid performance of the core medicines Cimzia, Vimpat and Neupro as well as Keppra in Europe and Japan.
For 2012, core earnings per share are estimated to be in the range of 1.60 euros - 1.70 euros, while revenue anticipated at about 3.1 billion euros.
UCB expects 2012 results to be driven by the continued growth of Cimzia, Vimpat and Neupro as well as by post-exclusivity expiry erosion for Keppra. In-line with UCB's dividend policy, that considers the long-term potential of UCB, the board recommends a gross dividend of 1.00 euros per share.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.